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Abstract
Background: WHO recommended incorporation of Haemophilus influenzae type b (Hib) vaccination into
immunization program. Indonesia would adopt Hib as a National Immunization Program in 2013. We aimed
at analyzing immunogenicity, safety, and consistency of a new combined DTP-HB-Hib (diphtheria-tetanus-
pertussis-Hepatitis B-Haemophilus influenza B) vaccine.
Methods: A prospective, randomized, double blind, multicenter, phase III study of Bio Farma DTP-HB-Hib vaccine
conducted in Jakarta and Bandung, August 2012 - January 2013.
Subjects were divided into three groups with different batch number. Healthy infants 6–11 weeks of age at
enrollment were immunized with 3 doses of DTP-HB-Hib vaccine with interval of 4 weeks, after birth dose of
hepatitis B vaccine. Blood samples obtained prior to vaccination and 28 days after the third dose. Safety measures
recorded until 28 days after each dose.
Results: Of 600 subjects, 575 (96 %) completed study protocol. After 3 doses, 100.0 and 96.0 % had anti-PRP
concentration ≥0.15 and ≥1.0 μg/ml. Anti-diphtheria and anti-tetanus concentration ≥0.01 IU/ml detected in 99.7
and 100.0 %; while concentration ≥0.1 IU/ml achieved in 84.0 and 97.4 %. Protective anti-HBs found in 99.3 %. The
pertussis vaccine response rate was 84.9 %.
None Serious Adverse events (SAEs) considered related to study vaccine or procedure.
Conclusions: The 3-dose of DTP-HB-Hib was immunogenic, well tolerated and suitable for replacement of
licensed-equivalent vaccines based on immunologic and safety profiles.
Trial registration: NCT01986335 – October 30th 2013.
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Background
Haemophilus Influenza type b is the leading cause of
childhood bacterial pneumonia, meningitis, and other
serious infections [1, 2]. In Indonesia, pneumonia and
meningitis cause an estimated 15.5 and 8.8 % of all deaths
recorded in under-five children, respectively [3]. Studies
have reported that the majority of Hib-related pneumonia
and meningitis occur in the first year of life [4, 5].
WHO has recommended the world wide incorporation
of Hib vaccination into all routine infant immunization
programs after 6 weeks of age, preferably as a diphtheria-
tetanus-pertussis (DTP) based combination allowing rapid
integration into existing DTP vaccination schedules [2, 6].
DTP-HB vaccine was licensed in Indonesia in 2004 and
has been routinely given to infants at 2, 3, 4 months of
age. Phase I and II study of DTP-HB-Hib vaccine showed
that DTP-HB vaccine was subsequently shown to be
immunogenic and well tolerated when mixed with
Hib vaccine and administered as a single injection (DTP-
HB-Hib) and already routinely used in many countries in
the world [7–9].
Meanwhile, introduction of such combined vaccines in
other middle and low income countries has been
followed by serious concerns about safety and adverse
events following immunization (AEFI). In 2008, the Ad-
visory Committee on Communicable Diseases (ACCD)
in Sri Lanka recommended to suspend the introduction
of DPT-Hepatitis B-Hib vaccine, following several cases
of hypotonic hyporesponsive episodes (HHE) which re-
sulted in five deaths and decided to reintroduce the vac-
cine after both the Committee and WHO (World Health
Organization) had found no conclusive evidence that
the vaccine caused the deaths in their investigations
[10]. In some developing countries, serious AEFI cases
occurred, including Bhutan, India, and Vietnam from
2009 to 2013 [11].
The objective of this study is to evaluate the immuno-
genicity, safety, and consistency of lots of a new combined
Bio Farma DTP-HB-Hib vaccine, when used as the pri-
mary vaccination of Indonesian infants according to EPI
schedule at 6, 10, and 14 weeks of age, after a birth dose
of hepatitis B vaccine, as recommended by WHO.
Methods
Study design and population
This was a prospective, randomized, double blind, multi-
center, phase III study of combined DTP-HB-Hib vaccine.
The study was conducted at 6 primary health centers in
Jakarta and Bandung from August 2012 through January
2013 and was approved by Health Research Ethics Com-
mittee Faculty of Medicine University of Indonesia – Dr.
Cipto Mangunkusumo Hospital and Health Research
Ethics Committee Faculty of Medicine Padjajaran Uni-
versity – Dr. Hasan Sadikin Hospital. Parents or legal
guardian of all subjects provided written informed
consent before enrollment. The study was conducted
in accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines.
The study population comprised of healthy infants
who were 6–11 weeks of age at enrollment, were born
between 37 and 42 weeks of gestation at delivery, with a
minimum birth weight of 2500–4000 g, and had received
a single dose of monovalent hepatitis B vaccine (Uniject™,
BioFarma) at 0–7 day after birth proved by written docu-
mentation of vaccination. Infants were excluded if they
had a history of allergic reaction likely to be stimulated by
any vaccine component; diphtheria, tetanus, pertussis,
hepatitis B, haemophilus influenzae type B infection; his-
tory of congenital or acquired immunodeficiency, uncon-
trolled coagulopathy or blood disorders, chronic illness, or
immunosuppressive condition; or if they were undergoing
immunosuppressive therapy or had received immuno-
globulin therapy or blood product prior to starting or dur-
ing the study; acute febrile illness at the time of the
vaccination; any previous vaccination other than oral polio
and BCG vaccine; and were participating in other clinical
study. Infants were withdrawn from the study if after
study vaccine administration they experienced fever
≥39.6 °C (axillary temperature) within 3 days of vaccin-
ation; persistent, inconsolable screaming or crying for
more than 3 h within 3 days; seizures within 7 days; en-
cephalopathy; hypotonic hyporesponsive episode within
3 days; thrombocytopenic purpura; or hypersensitivity re-
action to the study vaccine.
This study was designed to evaluate the consistency of
manufacturing based on immunogenicity and safety
outcomes from three lots of Bio Farma DTP-HB-Hib
vaccine. At the time of enrollment, subjects were assigned
randomly to one of three vaccine groups in a randomized
block permutation by using a randomization list.
Study vaccine
All DTP-HB-Hib vaccines used in this study were
developed and manufactured by Bio Farma, Bandung,
Indonesia. Three batches of vaccines were used, batch A
of which was from commercial scale, while B and C were
pilot scale of production. The study vaccines were admin-
istered at 6, 10, and 14 weeks of age, with the interval be-
tween doses was 4 weeks. The study vaccines were given
intramuscularly in the external anterolateral region of the
thigh. All three study vaccines had the same composition.
Each 0.5 ml dose contained ≥30 IU of purified diph-
theria toxoid, ≥60 IU of purified tetanus toxoid, ≥4 IU of
inactivated Bordetella pertussis, 10 μg hepatitis B surface
antigen (HBsAg, recombinant), 10 μg PRP (polyribosil-
ribitol-phosphate) conjugated to tetanus toxoid, 1.5 μg
alumunium phosphate, 4.5 mg sodium chloride, and
0.025 mg thimerosal.
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Immunogenicity assessment
Blood samples were collected prior to the first dose of
study vaccine and 28 days after the third dose to assess
antibody responses. Serum samples were tested for
antibodies against all vaccine antigens. Serology as-
says, except for anti-HBs, were conducted in Immun-
ology Laboratory of Product Evaluation Department
of Bio Farma by technicians who were blinded to group
assignment. Test for anti-HBs was conducted in a com-
mercial laboratory which had been approved by sponsor
Quality Assurance.
Antibodies to tetanus and diphtheria were measured
by using an enzyme-linked immunosorbent assay
(ELISA). An anti-diphtheria and anti-tetanus concentra-
tion of ≥0.01 IU/ml is generally accepted to be minimum
protective threshold, and a concentration of ≥0.1 IU/ml
is regarded as the standard protective threshold. Pertussis
antibodies were measured using microagglutination,
with a cut-off set at 1/40 dilution. A vaccine response
was defined as post-vaccination antibody titer four times
more than the pre-vaccination titer. Antibodies to hepa-
titis B surface (anti-HBs) were performed using Chemilu-
minescent Microparticle Immunoassay (CMIA) by
AUSAB, Abbott, with an assay cut-off set at 10 mIU/ml.
Antibodies to PRP were measured by using Improved
Phipps ELISA. A competitive Enzyme-Linked Im-
munosorbent Assay for measuring the levels of serum
antibody to Haemophilus influenzae type b [12]. Anti-
PRP concentration of ≥0.15 μg/ml is generally accepted to
be minimum protective threshold, and a concentra-
tion of ≥1.0 μg/ml is regarded as the long-term protection
threshold.
Safety assessment
Safety assessments were conducted by parents and study
personnel who were blinded to the three DTP-HB-Hib
vaccine lots. Study personnel monitored subjects for
30 min after each vaccination to detect immediate reac-
tion. Parents or legally guardians were given thermome-
ters and diary cards, and were asked to record the
occurrence and intensity (mild, moderate, or severe) of
local (i.e. pain, redness, swelling, and induration at
injection-site), and systemic (e.g. fever [≥38 °C] and irrit-
ability) reactions from day 0 (evening of vaccination)
through 28 days after each vaccination. For the analyses,
adverse events were graded from 1 to 3 in intensity. For
local reactions, grade 3 redness, swelling, or induration
was defined as areas >50 mm in diameter and grade 3 pain
was defined as cried when the leg was moved. For sys-
temic reactions, grade 3 fever was defined as axillary
temperature >39 °C and grade 3 irritability was defined as
inconsolable crying lasting more than 3 hours. For all
other general adverse events, grade 3 was defined as pre-
venting normal daily activities. The local and systemic
reactions were classified based on the Brighton Colla-
boration Local Reactions Working Group and Brighton
Collaboration Fever Working Group [13–15] with some
modifications suggested by US Food and Drug Adminis-
tration (FDA).
Parents of subjects were contacted by telephone 3 days
after each vaccination to ensure completeness of report-
ing and to screen for adverse events (AEs) requiring
medical evaluation or office visit, an emergency depart-
ment visit, or hospitalization. Serious adverse events
(SAEs) were recorded throughout the study and rated
by investigators for possible relationship to the study
vaccines. At each subsequent visit, the investigator
transcribed information from the diary cards onto the
Case Report Form, and asked about any other adverse
experiences that occurred after the period covered by
the diary card.
Statistical analysis
The target sample size was established at 600 assessable
infants for this study. A 10 % attrition rate was anticipated.
Data analyses were performed using the SPSS version 18.0
(SPSS, Chicago, IL) for Windows (Microsoft Corp., Red-
mond, WA, USA). Demographic data were expressed as
mean (SD) and range. The statistical significance of differ-
ences between the vaccine groups in demographic charac-
teristics was assessed by Chi-square test. P-values <0.05
were considered to be an indicator of statistically signifi-
cant difference between the vaccine groups.
The immunogenicity analyses were performed on the
per-protocol population, defined as subjects who re-
ceived the 3-dose primary series of the appropriately
assigned study vaccines, had all blood samples obtained
within the time intervals specified in the study protocol,
and had a valid post-vaccination serology test result.
Antibody seroprotection rates against diphtheria and
tetanus toxoids, hepatitis B surface, PRP, and vaccine
response rate to pertussis were calculated with 95 %
confidence intervals (CI). Geometric mean antibody
concentration (GMC) with 95 % CI were calculated
by taking the log-transformation of individual concentra-
tion and calculating the anti-log of the mean of these
transformed values. Exploratory analyses were performed
to compare GMCs and seroprotection rates between the
vaccine groups using Kruskal-Wallis and Chi-square or
Kolmogorov-Smirnov tests. The differences of antibody
concentration for each vaccine antigen before and
after 3-dose primary series of DTP-HB-Hib vaccine
were analyzed using Wilcoxon test.
Consistency was reached if the upper limits of the
95 % CI for the differences between groups in terms of
seroprotection rates for diphtheria, tetanus, hepatitis B
and PRP, and vaccine response rate for pertussis were all
below the predefined limit of 10 %. With a sample size
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of 600 subjects, the study had at least 90 % power to
conclude consistency for the co-primary objectives
(α = 5 %, reference rates of 90 % seroprotection against
Hib and 98 % for other parameters).
The safety analyses were based on the intention to
treat population, defined as all subjects who received at
least one dose of study vaccine. Exploratory analyses
were performed to compare incidences of solicited local
and systemic adverse events (any grade intensity) between
the vaccine groups using two-sided Fisher exact test.
Result
Study population
A total of 600 subjects were recruited and randomly
allocated to receive one of three vaccine groups, of whom
25 did not complete the study protocol: four withdrew
consent; ten migrated from the study area; and one
subject died due to sepsis as a bronchopneumonia com-
plication. The remaining ten subjects were eliminated
according to protocol for immunogenicity analyses: six
due to non-compliance with vaccination schedule and
four others due to protocol deviation for inclusion criteria
(age at enrollment >11 weeks). A total of 585 infants were
included in safety analyses, but only 575 infants were in-
cluded in immunogenicity analyses (Fig. 1). The demo-
graphic characteristics of the subjects enrolled in each
group were shown in Table 1. No clinically significant dif-
ferences with respect to gender and age were observed
among the three different candidate DTP-HB-Hib vaccine
lots used.
Immunogenicity assessment
Seroprotection and vaccine response rates for each anti-
gen in the study were summarized in Table 2, and
GMCs were listed in Table 3. In general, seroprotective
antibody concentration for all vaccine antigens post-
vaccination were no statistically significant differences
between all vaccine groups. There were significant dif-
ferences of antibody concentration for each vaccine anti-
gen before and after 3-dose primary series (p = 0.000).
Consistency of vaccines was demonstrated for all vaccine
antigens. The upper limit of the 95 % CI for the differ-
ence between the vaccine groups in seroprotection or
vaccine response rates was less than the predefined limit
of 10 % for all antigens.
Diphtheria and tetanus
After completion of 3-dose primary series, nearly all
subjects in each group achieved standard protective anti-
body concentration (≥0.1 IU/ml) against diphtheria
(86.6, 80.1 and 85.3 %, respectively) and tetanus (97.4,
97.9 and 96.8 %, respectively) toxoids (Table 2). No
significant differences in GMC values (p = 0.337 for anti-
diphtheria; and p = 0.479 for anti-tetanus), and sero-
protection rate for concentration ≥0.01 and ≥0.1 IU/ml
(p = 0.609 and p = 0.187 for anti-diphtheria; and p =
1.000 for anti-tetanus, respectively).
Pertussis
As shown in Table 2, nearly all subjects showed vaccine
response rates to pertussis antigen (89.2, 81.7 and
83.7 %, respectively). Individually, GMTs were signifi-
cantly higher in subjects in lot A group than in the two
other groups (p <0.000). Although there was a significant
difference in GMT, but no significant difference in the
four times antibody increase result (p = 0.104).
Hepatitis B
Nearly all subjects in each group achieved seroprotective
antibody concentration (≥10 mIU/ml) against hepatitis B
surface antigen (98.5, 99.5 and 100.0 %, respectively)
after hepatitis B vaccination at birth and 3-dose primary
600 enrolled and vaccinated
Group A (N=201) Group B (N=199) Group C (N=200)
196 completed
196 Analyses of safety
194 Analyses of immunogenicity
4 SAE
2 consent withdrawn








3 moved from study 
area
1 protocol violation
1 non-compliance with 
vaccination schedule
193 completed
193 Analyses of safety
191 Analyses of immunogenicity
1 protocol violation
1 non-compliance with 
vaccination schedule
196 completed
196 Analyses of safety
190 Analyses of immunogenicity
2 protocol violation
4 non-compliance with 
vaccination schedule
Fig. 1 Subject disposition
Rusmil et al. BMC Pediatrics  (2015) 15:219 Page 4 of 10
series (Table 2). Anti-HBs GMTs were also comparable
between the vaccine groups after hepatitis B vaccination
at birth and after 3-dose primary series, with a robust
anti-HBs response observed after the fourth dose in all
vaccine groups (Table 3). Individually, anti-HBs GMCs
were significantly lower in subjects in lot A group than
in the two other groups (p <0.001). Although there
was a significant difference in GMC, but no significant
difference in the four times antibody increase result
(p = 0.859).
Haemophilus influenzae type b
After completion of 3-dose primary series, all subjects
in each group had seroprotective anti-PRP concentra-
tion ≥0.15 μg/ml, and over 95 % from each group
had concentration ≥1.0 μg/ml (Table 2). Anti-PRP
GMCs pre-dose 1 and post-dose 3 were also compar-
able between the vaccine groups, with a robust anti-
PRP response observed after the third dose in all vac-
cine groups (Table 3). No significant differences in
GMC value (p = 0.174), and seroprotection rate for con-
centration ≥0.15 and ≥1.0 μg/ml (p = 1.000 and p = 0.704,
respectively).
Safety assessment
Each infant was counted only once and classified accord-
ing to the highest grade at vaccine injection-site. Rates
in lot B group were significantly lower than other
group, when compared statistically by Fisher’s exact
test (p = 0.033).
Immediate reactions
No anaphylactic or other severe reactions were reported
to occur within 30 minutes after any dose of study
vaccine.
Table 1 Summary of subject demographic characteristics
(Full Analysis Set)
Lot A Lot B Lot C Total
Total, N 201 199 200 600
Gender, n (%)
Male 114 (56.7) 110 (55.3) 97 (48.5) 321 (53.5)
Female 87 (43.3) 89 (44.7) 103 (51.5) 279 (46.5)
Age, week
Mean ± SD 8.3 ± 1.6 8.3 ± 1.5 8.4 ± 1.6 8.3 ± 1.6
Range 6–12 6–12 5–13 5–13
Table 2 Summary of seroprotection rates of antibody concentration (Per-Protocol Immunogenicity Population)
Antibody Assessment Criterion Lot A Lot B Lot C
Na %SPb 95 % CI N %SP 95 % CI N %SP 95 % CI
Diphtheria Pre-dose 1 ≥0.01 IU/ml 59 30.4 24.4–37.2 67 35.1 28.7–42.1 49 25.8 20.1–32.4
Pre-dose 1 ≥0.1 IU/ml 0 0.0 NA 7 3.7 1.8–7.4 3 1.6 0.5–4.5
Post-dose 3 ≥0.01 IU/ml 193 99.5 97.1–99.9 190 99.5 97.1–99.9 190 100.0 98.0–100.0
Post-dose 3 ≥0.1 IU/ml 168 86.6 81.1–90.7 153 80.1 73.9–85.1 162 85.3 79.5–89.6
Tetanus Pre-dose 1 ≥0.01 IU/ml 194 100.0 98.1–100.0 191 100.0 98.0–100.0 190 100.0 98.0–100.0
Pre-dose 1 ≥0.1 IU/ml 183 94.3 90.1–96.8 180 94.2 90.0–96.8 180 94.7 90.6–97.1
Post-dose 3 ≥0.01 IU/ml 194 100.0 98.1–100.0 191 100.0 98.0–100.0 190 100.0 98.0–100.0
Post-dose 3 ≥0.1 IU/ml 189 97.4 94.1–98.9 187 97.9 94.7–99.2 184 96.8 93.3–98.5
Pertussis Pre-dose 1 ≥40 (1/dil) 11 5.7 3.2–9.9 8 4.2 2.1–8.0 9 4.7 2.5–8.8
Pre-dose 1 ≥80 (1/dil) 3 1.5 0.5–4.4 3 1.6 0.5–4.5 2 1.1 0.3–3.8
Post-dose 3 ≥40 (1/dil) 172 88.7 83.4–92.4 158 82.7 76.7–87.4 161 84.7 80.6–87.1
Post-dose 3 ≥80 (1/dil) 157 80.9 74.8–85.8 140 73.3 66.6–79.1 143 75.3 68.6–81.1
Post-dose 3 VRRc 173 89.2 83.9–92.9 156 81.7 77.6–84.1 159 83.7 77.7–88.4
Hepatitis B Pre-dose 1 ≥10 mIU/ml 28 14.4 10.2–20.1 33 17.3 12.6–23.3 30 15.8 11.3–21.6
Post-dose 3 ≥10 mIU/ml 191 98.5 95.6–99.5 190 99.5 97.1–99.9 190 100.0 98.0–100.0
PRP (Hib) Pre-dose 1 ≥0.15 μg/ml 57 29.4 23.4–36.1 45 23.6 18.1–30.1 57 30.0 23.9–36.9
Pre-dose 1 ≥1.0 μg/ml 22 11.3 7.6–16.6 10 5.2 2.9–9.4 19 10.0 6.5–15.1
Post-dose 3 ≥0.15 μg/ml 194 100.0 98.0–100.0 191 100.0 98.0–100.0 190 100.0 98.0–100.0
Post-dose 3 ≥1.0 μg/ml 188 96.5 93.4–98.6 183 95.8 92.0–97.9 181 95.3 91.2–97.5
NA indicates not available
aN = number of subjects with a valid serology result pre-dose 1 and post-dose 3
b%SP = seroprotection rate
cVRR (Vaccine Response Rate) is defined as ≥4 times more than the pre-vaccination concentration
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Local and systemic reactions
Figures 2 and 3 show the proportions of subjects in each
group who reported the incidences of solicited local (in-
jection-site) and systemic reactions within 72 hours after
each vaccination. The most frequently reported solicited
local reaction in all groups was injection-site pain
(Fig. 2). The majority of local reactions in all vaccine
groups were mild and resolved spontaneously within
72 hours after vaccination. Pain, swelling, and induration
occurred with a similar frequency in all vaccine groups.
Exploratory analyses showed that the incidence of red-
ness was significantly higher in subjects in lot A group
than the two other groups (p = 0.033).
The most common solicited systemic reactions were
irritability (Fig. 3). Fever occurred with a similar frequency
between the vaccine groups. Most of fever reactions were
mild or moderate in intensity and short in duration.
Severe fever (>39 °C) was reported by 0.5 % of lot A recip-
ients, 1.0 % of lot B recipients, and 1.5 % of lot C recipi-
ents after the third dose. No hospitalizations because of
fever were reported for subjects in either group. Each
infant was counted only once and classified according to
the highest grade.
Serious adverse events
From the time of the first dose to 35 days after the third
dose, there were 11 SAEs in 10 subjects: 3 (1.5 %) subjects
in lot A group, 1 (0.5 %) in lot B group, and 6 (3.0 %) in lot
C group. Seven subjects (two in lot A group, and five in lot
C group) were hospitalized for 2–4 days due to acute diar-
rhea. Four subjects were hospitalized due to bronchopneu-
monia: three subjects (one in each group) recovered after
treatment and one subject (lot A group) subsequently died
due to sepsis. This subject from group A were hospitalized
twice due to bronchopneumonia. Those SAEs were consid-
ered as coincidence and unrelated to the study vaccine and
the study proceduredue to analysis from National Adverse
Even Following Immunization (AEFI) committee.
Discussion
This study analyzed the immunogenicity, safety, and
consistency of the new combined DTP-HB-Hib vaccine
produced by Bio Farma, when administered according
the early and accelerated EPI schedule at 6, 10 and
14 weeks of age, with prior administration of a birth
dose of hepatitis B vaccine, as recommended in
Indonesia. The present study was conducted to generate
data to support licensure of combined DTP-HB-Hib vac-
cine in Indonesia.
Combined vaccines have become an integral part of
global childhood immunization programs and are gener-
ally highly acceptable to parents due to the relative ease
of administering multiple antigens at a single visit.
Multivalent vaccines have been shown to minimize
the number of injection, increase compliance with
the immunization schedule, increase immunization
coverage, decrease exposure to vaccine excipients
[16], and reduce logistic costs of vaccine delivery in-
cluding number of visits to health centers, number
of syringes and needles required, and necessary stor-
age space [17, 18].
An important consideration in national immunization
programs, particularly in the developing countries, is the
cost effectiveness of vaccines. Gessner et al. found that
for the 2007 Indonesian birth cohort, Hib vaccine would
prevent meningitis in 1 of every 179 children, pneu-
monia in 1 of every 18 children, and 4.9 % of mortality
among under-five children. The total incremental societal
costs of introducing Hib vaccine in monovalent and
multivalent (DTP-HB-Hib) presentations were, respect-
ively, US$11.74 and $8.93 for each child. Annual dis-
counted treatment costs averted amounted to 20 % of
multivalent vaccine costs. For the multivalent vaccine,
the incremental costs for every discounted death and
disability adjusted life-year averted amounted to US$3102
and $74, respectively, versus $4438 and $102 for monova-
lent vaccine [19].
Table 3 Summary of geometric mean antibody concentration (Per-Protocol Immunogenicity Population)
Antibody Assessment Lot A Lot B Lot C
GMC 95 % CI GMC 95 % CI GMC 95 % CI
Diphtheria Pre-dose 1 0.004 0.003–0.004 0.004 0.004–0.006 0.004 0.003–0.004
Post-dose 3 0.37 0.30–0.44 0.30 0.25–0.36 0.34 0.29–0.40
Tetanus Pre-dose 1 1.85 1.48–2.30 1.79 1.43–2.23 1.98 1.61–2.44
Post-dose 3 1.63 1.38–1.93 1.58 1.34–1.86 1.38 1.15–1.65
Pertussis Pre-dose 1 6.49 5.96–7.07 6.42 5.89–7.00 6.22 5.75–6.74
Post-dose 3 168.81 137.86–206.71 100.55 81.31–124.35 106.72 87.02–130.89
Hepatitis B Pre-dose 1 0.005 0.003–0.008 0.007 0.004–0.01 0.006 0.003–0.01
Post-dose 3 317.61 242.07–416.74 514.16 419.68–629.91 574.55 490.12–673.52
PRP (Hib) Pre-dose 1 0.008 0.005–0.01 0.005 0.003–0.007 0.007 0.005–0.01
Post-dose 3 22.13 18.32–26.73 17.72 14.50–21.65 20.32 16.50–25.03
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PRP-TT was considered to be efficacious and was ap-
proved for use in infants beginning at 6 weeks of age,
without the need to perform an efficacy trial. Conceivably,
the lower immunogenicity of the combination vaccines
might not decrease protection among vaccinated children





Fig. 2 Reports of local reactions (a, Pain; b. Redness; c, Swelling; d, Induration) occurring within 72 hours after administration of DTP-HB-Hib
combined vaccine
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control of Hib colonization or transmission [20]. A further
surveillance study will be required to evaluate decline inci-
dence of Hib disease associated with the investigational
DTP-HB-Hib combination vaccine.
The majority of subjects (ranging between 84 and
100 %) in each vaccine group achieved serum antibody
concentration indicative of protection against diphtheria,
tetanus, pertussis, hepatitis B, and Hib after 3-dose pri-
mary vaccination series. Other studies conducted in India
and Philippines that used the same accelerated EPI sched-
ule but vaccinated with different DTP-HB-Hib vaccine
showed seroprotection rates similar to those observed in
the present study [7, 8, 18, 21, 22].
Gatchalian et al. vaccinated 94 healthy Philippines infants
with DTPw-HBV/Hib10 (Tritanrix™-HepB and Hiberix™,
GlaxoSmithKline Biologicals, Rixensart, Belgium) with a
schedule of 6, 10, and 14 weeks of age, without prior hepa-
titis B vaccination at birth. One month after the third dose,
100.0 and 94.7 % of subjects had anti-PRP concentration
≥0.15 and ≥1.0 μg/ml; 92.6, 100.0 and 78.5 % of subjects
had seroprotective concentration against diphtheria, tet-
anus, and hepatitis B; and 98.9 % had pertussis vaccine
response, respectively [8]. Chatterjee et al. vaccinated 89
healthy Indian infants, who had received one dose of the
Hep B vaccine within 1 week of birth, with DTPw-HBV/
Hib10 (Tritanrix™-HepB and Hiberix™) with a schedule of
6, 10, and 14 weeks of age. One month after the third dose,
100.0 % of subjects had anti-PRP concentration ≥1.0 μg/ml
and seroprotective concentration against tetanus and
hepatitis B; and 98.9 % of subjects had anti-diphtheria
≥0.1 IU/ml and vaccine response for anti-BPT (Borde-
tella pertussis) [22].
Of interest is the finding that in this study, transpla-
centally acquired antibody concentration for anti-tetanus
toxoid were present in all subjects before primary vaccin-
ation series. High transplacentally acquired anti-tetanus
toxoid concentration are common in Indonesia, where
programs for the prevention of neonatal tetanus are im-
plemented by vaccination to pregnant women. In addition,
30.4, 15.8 and 27.7 % of subjects had seroprotective anti-
body concentration against diphtheria, hepatitis B surface,
and Hib before primary vaccination series. Our results in-
dicated that the immune response to the investigational
DTP-HB-Hib combination vaccine is not negatively influ-
enced by the presence of transplacentally acquired anti-
body concentration. Although there was evidence of the
presence transplacentally acquired antibodies at 6–11
weeks of age, the GMC values showed a marked increase
after 3-dose primary vaccination series, thereby demon-
strating a vaccine response in the subjects.
Dose 1 Dose 2                               Dose 3
Dose 1 Dose 2                              Dose 3
A
B
Fig. 3 Reports of systemic reactions (a, Fever; b, Irritability) occurring within 72 hours after administration of DTP-HB-Hib combined vaccine
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During the study period, the investigational DTP-HB-
Hib combination vaccine elicited similar proportions of
solicited local and systemic reaction between the vaccine
groups. The incidence of local and systemic reactions
decreased with successive doses of primary vaccination.
Pain and irritability were the most frequent solicited
local and systemic reactions in each vaccine group.
Fewer than 3 % of local or systemic reactions were re-
ported as severe after any dose in either group. Fever of
any severity was reported at lower rates among all sub-
jects after any dose. Fever with the first dose is of par-
ticular importance, because fever in young infants is
often considered as possibly representing sepsis and thus
may lead to medical and laboratory evaluation, including
a visit to the physician’s office or emergency department
and diagnostic testing for possible systemic infection.
In the other studies, local reactions including redness,
swelling, and pain at the site of injection usually started
within 1 day after vaccination and last for 1–3 days. Less
commonly, children may develop a fever or be irritable
for a short period. When the Hib vaccine was given at
the same time as DTP, the rate of fever or irritability, or
both, was no higher than when DTP was given alone [2].
In this study, the percentage of local and systemic reac-
tions following 3-dose primary vaccination series was
within the range reported for DTP-HB-based combination
vaccine and licensed-equivalent vaccine [9, 21, 23–25].
Addition of each vaccine component to the DTP-HB-Hib
combination kept safety profile of the investigational
DTP-HB-Hib combination vaccine appeared to be similar
to that of the DTP-HB-based combination vaccine and
licensed-equivalent vaccines.
Lot-to-lot consistency for the investigational DTP-HB-
Hib combination vaccine was demonstrated for all vaccine
antigens. The upper limit of the 95 % CI for the difference
between the vaccine groups in seroprotection or vaccine
response rates was less than the predefined limit of 10 %
for all antigens. Based on this finding, data for the three
vaccine lots used in this study were pooled for comparison
against each lot. This result provided empirical evidence
of consistency between lot productions, which had also
been verified through quality control protocols.
In Bhutan, five cases of encephalopathy and/or meningo-
encephalitis were reported after introduction of pentava-
lent vaccination in 2009. In 2012–2013, India introduced
the similar vaccine resulted in 83 AEFI cases. As many as
43 serious AEFI cases including 27 fatal outcomes were
also reported in Vietnam after introduction of pentavalent
vaccine from Crucell in 2010–2013. All of these serious
AEFI cases in each country were reviewed with independ-
ent national and international experts [11].
The safety profile of DTP-HB-Hib vaccine could be
explored further in next phase. Some serious AEFIs which
had not occurred in phase three study would occurred in
phase four study. Hence, more accurate safety profile
could be obtained for implementation of combination vac-
cines in the future.
Conclusions
The investigational DTP-HB-Hib combination vaccine
has proven high immunogenicity for all vaccine antigens
and an acceptable safety profile. This study supports the
conclusion that the Bio Farma DTP-HB-Hib combin-
ation vaccine is a suitable replacement for the licensed-
equivalent vaccines based on similar safety profiles, and
antibody responses to the vaccine antigens after 3-dose
primary vaccination series. Replacement of standard
DTP-HB vaccine, which already has high coverage, with
DTP-HB-Hib can be done without modifying the existing
EPI schedule. This should facilitate widespread coverage
of Hib vaccination and their rapid incorporation into the
EPI, and WHO recommendations for controlling Hib dis-
ease which are responsible for substantial mortality and
morbidity worldwide.
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